Magnetic resonance spectroscopy in epilepsy
Briellmann, Regula S., Wellard, R. Mark, & Jackson, Graeme D. (2005) Magnetic resonance spectroscopy in epilepsy. In Gillard, Jonathan H., Waldman, Adam D., & Barker, Peter B. (Eds.) Clinical MR neuroimaging diffusion, perfusion and spectroscopy. Cambridge University Press, Cambridge, pp. 488-508.
• The clinical aims of MR spectroscopy (MRS) in
seizure disorders are to help identify, localize
and characterize epileptogeic foci.
• Lateralizing MRS abnormalities in temporal lobe
epilepsy (TLE) may be used clinically in combi-
nation with structural and T2measurements.
• Characteristic metabolite abnormalities are
decreased N-acetylaspartate (NAA) with
increased choline (Cho) and myoinositol (mI)
• Contralateral metabolite abnormalities are
frequently seen in TLE, but are of uncertain
• In extra-temporal epilepsy, metabolite abnor-
malities may be seen where MR imaging (MRI)
is normal; but may not be sufficiently local-
ized to be useful clinically.
• MRS may help to characterize epileptogenic
lesions visible on MRI (aggressive vs. indolent
• Spectral editing techniques are required to
evaluate specific epilepsy-relevant metabolites
(e.g. -aminobutyric acid (GABA)) which may
be useful in drug development and evaluation.
• MRS with phosphorus (31P) and other nucleii
probe metabolism of epilepsy, but are less
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Repository Staff Only: item control page